

GLOBAL MARKETS FOR CONTRACT PHARMACEUTICAL MANUFACTURING, RESEARCH AND PACKAGING



PHM043F
June 2015

Shalini Shahani Dewan
Project Analyst

ISBN: 1-62296-112-9



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
INTENDED AUDIENCE	2
SCOPE OF REPORT	3
METHODOLOGY AND INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 EXECUTIVE SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR CONTRACT PHARMACEUTICAL MANUFACTURING, RESEARCH AND PACKAGING BY SEGMENT, THROUGH 2019 (\$ BILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR CONTRACT PHARMACEUTICAL MANUFACTURING, RESEARCH AND PACKAGING BY SEGMENT, 2012-2019 (\$ BILLIONS)</i>	7
CHAPTER 3 OVERVIEW	10
OUTSOURCING	10
HISTORY OF OUTSOURCING	10
<i>TABLE 1 KEY DEVELOPMENTS IN THE HISTORY OF OUTSOURCING</i>	11
KEY COMPONENTS OF A SUCCESSFUL OUTSOURCING STRATEGY	13
CORE FUNCTIONAL AREAS THAT NEED CONSTANT MONITORING	13
Cost Management	13
Communication Management	14
Performance Management	14
Risk Management	14
Crisis Management	14
Knowledge Transfer Management	14
Relationship Management	14
CONTRACT MANUFACTURING	15
TYPES OF CONTRACT MANUFACTURERS	15
Those Who "Supply"	15
Those Who "Toll"	15
Types of Toll Manufacturers	16
Sellers of Excess Capacity	16
Suitable Service Providers	16
Academic Institutions	16
FOUR STAGES OF CONTRACT MANUFACTURING	16
Program Initiation	16
Service Implementation	17
Final Agreement	17
Program Closure	17
CORE CAPABILITIES OF CMOS	17

TOPIC	PAGE NO.
REASONS FOR PHARMACEUTICAL CONTRACT MANUFACTURING	18
Reduce and Control Operating Costs	18
Focus on Core Competencies	18
Access to Advanced Technologies	18
Risk Sharing	18
BENEFITS OF CONTRACT MANUFACTURING	19
SUCCESS FACTORS IN CONTRACT MANUFACTURING	19
Product Quality	20
Cost-Competitiveness	20
Delivery Schedule	20
CM/Customer Relationship	20
RISKS IN CONTRACT MANUFACTURING	20
Lack of Control	20
Relationships	20
Quality Concerns	21
Intellectual Property Loss	21
Other Risks	21
Capacity Constraints	21
Loss of Flexibility and Responsiveness	21
<i>TABLE 2 ADVANTAGES AND DISADVANTAGES OF CONTRACT MANUFACTURING</i>	21
SYSTEMIC APPROACH FOR SELECTING A CONTRACT MANUFACTURER	22
Getting the List	23
Make a List	23
Contact CMOs and Create Request for Quote Package	23
Site Visit	23
Negotiation with the Finalists	24
CONTRACT RESEARCH ORGANIZATIONS	24
SERVICES OFFERED BY A CRO	24
BENEFITS OF USING A CRO	25
SELECTING A CRO	25
CLIENT-CRO RELATIONSHIP	26
KEYS FOR A SUCCESSFUL CLIENT-CRO RELATIONSHIP	27
Selecting the Right Partner	27
Avoiding Unclear Expectations and Vague or Conflicting Requirements	27
Avoiding Micro-managing Every Step	27
Setting Realistic Expectations	27
Vendor's Input	28
Expecting a CRO to Replicate Client's Processes	28
Promising Based on Capabilities	28
Understanding the Project's Goals	28
Managing Communications	28
Problem-solving Aptitude	28
CONTRACT PACKAGING	29
TYPES OF PACKAGING	29
Primary Packaging	29
Secondary Packaging	29
Tertiary Packaging	30

TOPIC	PAGE NO.
REASONS A CONTRACT PACKAGER MIGHT BE NEEDED	30
CHOOSING A CONTRACT PACKAGER	31
Location	31
Relevant Experience	31
Ethics	31
Cost	31
Communication	31
Controls	31
Quality	32
ETHICAL STANDARDS FOR CONTRACT PACKAGERS	32
CHAPTER 4 REGULATORY ASPECTS	34
WARNING LETTERS	35
<i>TABLE 3 PHARMACEUTICAL MANUFACTURERS THAT RECEIVED WARNING LETTERS, 2014</i>	36
<i>TABLE 4 PHARMACEUTICAL MANUFACTURERS THAT RECEIVED WARNING LETTERS, 2013</i>	37
<i>TABLE 5 PHARMACEUTICAL MANUFACTURERS THAT RECEIVED WARNING LETTERS, 2012</i>	38
<i>TABLE 6 PHARMACEUTICAL MANUFACTURERS THAT RECEIVED WARNING LETTERS, 2011</i>	39
REGULATORY APPROVALS	39
<i>TABLE 7 REGULATORY APPROVALS OF CONTRACT MANUFACTURERS AND FACILITIES, 2014</i>	40
<i>TABLE 8 REGULATORY APPROVALS OF CONTRACT MANUFACTURERS AND FACILITIES, 2013</i>	41
<i>TABLE 9 REGULATORY APPROVALS OF CONTRACT MANUFACTURERS AND FACILITIES, 2012</i>	41
<i>TABLE 10 REGULATORY APPROVALS OF CONTRACT MANUFACTURERS AND FACILITIES, 2011</i>	42
CHAPTER 5 NEW DEVELOPMENTS	44
ACTAVIS PLC	44
LONZA	44
BRISTOL-MYERS SQUIBB	46
ABBVIE	47
ALBANY MOLECULAR RESEARCH INC.	48
BASF	49
EVOTEC AG	50
HOSPIRA	52
MALLINCKRODT	52
DR. REDDY'S LABORATORIES	52
PERRIGO CO. PLC	53
PATHEON	54
OTHER	54
CHAPTER 6 MARKET ANALYSIS: CONTRACT MANUFACTURING	58
CONTRACT MANUFACTURING OF BULK DRUGS/APIS	58
MARKET OVERVIEW	59

TOPIC	PAGE NO.
MARKET REVENUE	61
<i>TABLE 11 GLOBAL REVENUE FOR BULK DRUG/APIS THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	61
<i>FIGURE 1 GLOBAL REVENUE FOR BULK DRUG/APIS THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ MILLIONS)</i>	62
CONTRACT MANUFACTURE OF DOSAGE FORMS	62
MARKET BY TYPE	63
Market Overview	64
Market Revenue	64
<i>TABLE 12 GLOBAL REVENUE FOR CONTRACT MANUFACTURING OF VARIOUS DOSAGE FORMS, THROUGH 2019 (\$ MILLIONS)</i>	65
<i>FIGURE 2 GLOBAL REVENUE FOR CONTRACT MANUFACTURING OF VARIOUS DOSAGE FORMS, 2012-2019 (\$ MILLIONS)</i>	65
MARKET BY REGION	66
Solid Dosage Form	66
Market Overview	66
Market Revenue	67
<i>TABLE 13 GLOBAL REVENUE FOR SOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	68
<i>FIGURE 3 GLOBAL REVENUE FOR SOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ MILLIONS)</i>	68
Liquid Dosage Forms	68
Market Overview	69
Non-sterile Formulations	70
Sterile Formulations	71
Market Revenue for Non-sterile Formulations	71
<i>TABLE 14 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (NON-STERILE) THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	72
<i>FIGURE 4 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (NON-STERILE) THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ MILLIONS)</i>	72
Market Revenue for Sterile Formulations	73
<i>TABLE 15 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (STERILE) THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	73
<i>FIGURE 5 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (STERILE) THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ MILLIONS)</i>	73
Semisolid Dosage Forms	74
Market Overview	74
Market Revenue	75
<i>TABLE 16 GLOBAL REVENUE FOR SEMISOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	76
<i>FIGURE 6 GLOBAL REVENUE FOR SEMISOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ MILLIONS)</i>	76
MARKET BY FORMULATIONS	76
Solid Dosage Forms	77
Market Revenue for Solid Dosage Forms	77
<i>TABLE 17 GLOBAL REVENUE FOR SOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, THROUGH 2019 (\$ MILLIONS)</i>	78
<i>FIGURE 7 GLOBAL REVENUE FOR SOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2012-2019 (\$ MILLIONS)</i>	78
Market Share of Solid Dosage Formulations	78

TOPIC	PAGE NO.
<i>TABLE 18 GLOBAL MARKET SHARE OF SOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)</i>	78
<i>FIGURE 8 GLOBAL MARKET SHARE OF SOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)</i>	79
Liquid Dosage Forms	79
Market Revenue of Non-sterile Forms	80
<i>TABLE 19 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (NON-STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, THROUGH 2019 (\$ MILLIONS)</i>	80
<i>FIGURE 9 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (NON-STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2012-2019 (\$ MILLIONS)</i>	81
Market Share of Non-sterile Formulations	81
<i>TABLE 20 GLOBAL MARKET SHARE OF LIQUID DOSAGE FORMS (NON-STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)</i>	81
<i>FIGURE 10 GLOBAL MARKET SHARE OF LIQUID DOSAGE FORMS (NON-STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)</i>	82
Market Revenue for Sterile Formulations	82
<i>TABLE 21 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, THROUGH 2019 (\$ MILLIONS)</i>	83
<i>FIGURE 11 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2012-2019 (\$ MILLIONS)</i>	83
Market Share of Sterile Formulations	84
<i>TABLE 22 GLOBAL MARKET SHARE OF LIQUID DOSAGE FORMS (STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)</i>	84
<i>FIGURE 12 GLOBAL MARKET SHARE OF LIQUID DOSAGE FORMS (STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)</i>	84
Semisolid Dosage Forms	84
Market Revenue	85
<i>TABLE 23 GLOBAL REVENUE FOR SEMISOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, THROUGH 2019 (\$ MILLIONS)</i>	86
<i>FIGURE 13 GLOBAL REVENUE FOR SEMISOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2012-2019 (\$ MILLIONS)</i>	86
Market Share	86
<i>TABLE 24 GLOBAL MARKET SHARE OF SEMISOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)</i>	87
<i>FIGURE 14 GLOBAL MARKET SHARE OF SEMISOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)</i>	87
ADVANCED DRUG DELIVERY PRODUCTS THROUGH CONTRACT MANUFACTURING	87
MARKET OVERVIEW	88
<i>TABLE 25 SOME CONTRACTING COMPANIES PROVIDING DRUG-DELIVERY SYSTEMS</i>	90
MARKET BY REGION	91
<i>TABLE 26 GLOBAL REVENUE FOR ADVANCED DRUG DELIVERY SYSTEMS THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	91
<i>FIGURE 15 GLOBAL REVENUE FOR ADVANCED DRUG DELIVERY SYSTEMS THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ MILLIONS)</i>	91
MARKET BY FORMULATION	92
<i>TABLE 27 GLOBAL REVENUE FOR ADVANCED DRUG DELIVERY SYSTEMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, THROUGH 2019 (\$ MILLIONS)</i>	93

TOPIC	PAGE NO.
<i>FIGURE 16 GLOBAL REVENUE FOR ADVANCED DRUG DELIVERY SYSTEMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2012-2019 (\$ MILLIONS)</i>	93
MARKET SHARE	94
<i>TABLE 28 GLOBAL MARKET SHARE OF ADVANCED DRUG DELIVERY SYSTEMS THROUGH CONTRACT MANUFACTURING BY TYPE, 2013 (%)</i>	94
<i>FIGURE 17 GLOBAL MARKET SHARE OF ADVANCED DRUG DELIVERY SYSTEMS THROUGH CONTRACT MANUFACTURING BY TYPE, 2013 (%)</i>	95
CONTRACT MANUFACTURE OF OTC AND NUTRACEUTICALS	95
MARKET BY REGION	95
Market Revenue	97
<i>TABLE 29 GLOBAL REVENUE FOR OTC AND NUTRACEUTICALS THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ BILLIONS)</i>	97
<i>FIGURE 18 GLOBAL REVENUE FOR OTC AND NUTRACEUTICALS THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ BILLIONS)</i>	98
MARKET BY FORMULATION	98
<i>TABLE 30 GLOBAL REVENUE FOR OTC AND NUTRACEUTICALS THROUGH CONTRACT MANUFACTURING BY FORMULATION, THROUGH 2019 (\$ BILLIONS)</i>	99
<i>FIGURE 19 GLOBAL REVENUE FOR OTC AND NUTRACEUTICALS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2012-2019 (\$ BILLIONS)</i>	99
Market Share	99
<i>TABLE 31 GLOBAL MARKET SHARE OF OTC AND NUTRACEUTICALS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)</i>	99
<i>FIGURE 20 GLOBAL MARKET SHARE OF OTC AND NUTRACEUTICALS THROUGH CONTRACT MANUFACTURING BY DOSAGE TYPE, 2013 (%)</i>	100
CONTRACT MANUFACTURING OF BULK DRUGS AND DOSAGE FORMS BY APPLICATION/THERAPEUTIC AREA	100
CARDIOVASCULARS	100
ANTIBIOTICS	101
ANALGESICS	102
ONCOLOGY	102
ANTIVIRALS	103
REPRODUCTIVE DRUG PRODUCTS	104
OTHER DRUGS	105
MARKET REVENUE	105
<i>TABLE 32 GLOBAL REVENUE FOR CONTRACT MANUFACTURING DRUGS BY THERAPEUTIC CATEGORY, THROUGH 2019 (\$ MILLIONS)</i>	106
<i>FIGURE 21 GLOBAL REVENUE FOR CONTRACT MANUFACTURING DRUGS BY THERAPEUTIC CATEGORY, 2012-2019 (\$ MILLIONS)</i>	106
MARKET SHARE	107
<i>TABLE 33 GLOBAL MARKET SHARE OF VARIOUS THERAPEUTIC CATEGORIES IN CONTRACT MANUFACTURING, 2013 (%)</i>	107
<i>FIGURE 22 GLOBAL MARKET SHARE OF VARIOUS THERAPEUTIC CATEGORIES IN CONTRACT MANUFACTURING, 2013 (%)</i>	107
CHAPTER 7 MARKET ANALYSIS: CONTRACT RESEARCH	109
MARKET BY DISCIPLINE	109
MARKET OVERVIEW	110
MARKET REVENUE	112

TOPIC	PAGE NO.
<i>TABLE 34 GLOBAL REVENUE FOR CONTRACT RESEARCH BY DISCIPLINE, THROUGH 2019 (\$ MILLIONS)</i>	113
<i>FIGURE 23 GLOBAL REVENUE FOR CONTRACT RESEARCH BY DISCIPLINE, 2012-2019 (\$ MILLIONS)</i>	113
MARKET SHARE	113
<i>TABLE 35 GLOBAL MARKET SHARE OF CONTRACT RESEARCH BY DISCIPLINE, 2013 (%)</i>	113
<i>FIGURE 24 GLOBAL MARKET SHARE OF CONTRACT RESEARCH BY DISCIPLINE, 2013 (%)</i>	114
MARKET BY REGION	114
MARKET OVERVIEW	115
MARKET REVENUE	116
<i>TABLE 36 GLOBAL REVENUE FOR CONTRACT RESEARCH BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	117
<i>FIGURE 25 GLOBAL REVENUE FOR CONTRACT RESEARCH MARKET BY REGION, 2012-2019 (\$ MILLIONS)</i>	117
MARKET SHARE	117
<i>TABLE 37 GLOBAL MARKET SHARE OF CONTRACT RESEARCH BY REGION, 2013 (%)</i>	117
<i>FIGURE 26 GLOBAL MARKET SHARE OF CONTRACT RESEARCH MARKET BY REGION, 2013 (%)</i>	118
CONTRACT CLINICAL RESEARCH MARKET BY REGION	118
<i>TABLE 38 GLOBAL REVENUE FOR CONTRACT CLINICAL RESEARCH BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	119
<i>FIGURE 27 GLOBAL REVENUE FOR CONTRACT CLINICAL RESEARCH BY REGION, 2012-2019 (\$ MILLIONS)</i>	120
CONTRACT DRUG DISCOVERY MARKET BY REGION	120
<i>TABLE 39 GLOBAL REVENUE FOR CONTRACT DRUG DISCOVERY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	121
<i>FIGURE 28 GLOBAL REVENUE FOR CONTRACT DRUG DISCOVERY BY REGION, 2012-2019 (\$ MILLIONS)</i>	121
CONTRACT ANALYTICAL RESEARCH MARKET BY REGION	122
<i>TABLE 40 GLOBAL REVENUE FOR CONTRACT ANALYTICAL RESEARCH MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	123
<i>FIGURE 29 GLOBAL REVENUE FOR CONTRACT ANALYTICAL RESEARCH MARKET BY REGION, 2012-2019 (\$ MILLIONS)</i>	124
OTHER CONTRACT RESEARCH ACTIVITIES MARKET BY REGION	124
<i>TABLE 41 GLOBAL REVENUE FOR OTHER CONTRACT RESEARCH MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	125
<i>FIGURE 30 GLOBAL REVENUE FOR OTHER CONTRACT RESEARCH MARKET BY REGION, 2012-2019 (\$ MILLIONS)</i>	125
MARKET BY THERAPEUTIC AREA	125
CARDIOLOGY	126
ONCOLOGY	127
INFLAMMATION AND IMMUNOLOGY	127
NEUROSCIENCE	128
VACCINES	129
OTHERS	130
MARKET REVENUE	131
<i>TABLE 42 GLOBAL REVENUE FOR CONTRACT RESEARCH BY THERAPEUTIC AREA, THROUGH 2019 (\$ MILLIONS)</i>	132

TOPIC	PAGE NO.
<i>FIGURE 31 GLOBAL REVENUE FOR CONTRACT RESEARCH BY THERAPEUTIC AREA, 2012-2019 (\$ MILLIONS)</i>	132
MARKET SHARE	133
<i>TABLE 43 GLOBAL MARKET SHARE OF CONTRACT RESEARCH BY THERAPEUTIC AREA, 2013 (%)</i>	133
<i>FIGURE 32 GLOBAL MARKET SHARE OF CONTRACT RESEARCH BY THERAPEUTIC AREA, 2013 (%)</i>	133
CHAPTER 8 MARKET ANALYSIS: CONTRACT PACKAGING	135
MARKET BY TYPE	135
MARKET OVERVIEW	136
MARKET REVENUE	137
<i>TABLE 44 GLOBAL REVENUE OF CONTRACT PACKAGING BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	137
<i>FIGURE 33 GLOBAL REVENUE OF CONTRACT PACKAGING BY TYPE, 2012-2019 (\$ MILLIONS)</i>	138
PRIMARY CONTAINERS BY TYPE	138
<i>TABLE 45 GLOBAL REVENUE OF PRIMARY PACKAGING BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	139
<i>FIGURE 34 GLOBAL REVENUE OF PRIMARY PACKAGING BY TYPE, 2012-2019 (\$ MILLIONS)</i>	139
MARKET SHARE	140
<i>TABLE 46 GLOBAL MARKET SHARE OF CONTRACT PACKAGING BY TYPE, 2013 (%)</i>	140
<i>FIGURE 35 GLOBAL MARKET SHARE OF CONTRACT PACKAGING BY TYPE, 2013 (%)</i>	140
MARKET BY REGION	141
MARKET OVERVIEW	141
MARKET REVENUE	143
<i>TABLE 47 GLOBAL REVENUE OF CONTRACT PACKAGING BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	143
<i>FIGURE 36 GLOBAL REVENUE OF CONTRACT PACKAGING BY REGION, 2012-2019 (\$ MILLIONS)</i>	143
MARKET SHARE	144
<i>TABLE 48 GLOBAL MARKET SHARE OF CONTRACT PACKAGING BY REGION, 2013 (%)</i>	144
<i>FIGURE 37 GLOBAL MARKET SHARE OF CONTRACT PACKAGING BY REGION, 2013 (%)</i>	144
PRIMARY PACKAGING BY REGION	145
<i>TABLE 49 GLOBAL REVENUE FOR PRIMARY PACKAGING BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	146
<i>FIGURE 38 GLOBAL REVENUE FOR PRIMARY PACKAGING BY REGION, 2012-2019 (\$ MILLIONS)</i>	146
SECONDARY PACKAGING BY REGION	147
<i>TABLE 50 GLOBAL REVENUE FOR SECONDARY PACKAGING BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	148
<i>FIGURE 39 GLOBAL REVENUE FOR SECONDARY PACKAGING BY REGION, 2012-2019 (\$ MILLIONS)</i>	148
OTHER TYPES OF PACKAGING BY REGION	149
<i>TABLE 51 GLOBAL REVENUE FOR OTHER PACKAGING BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	150
<i>FIGURE 40 GLOBAL REVENUE FOR OTHER PACKAGING BY REGION, 2012-2019 (\$ MILLIONS)</i>	150

TOPIC	PAGE NO.
CHAPTER 9 INDUSTRY STRUCTURE	152
CONTRACT MANUFACTURING	152
MARKET LEADERS	152
<i>TABLE 52 SERVICES PROVIDED BY CONTRACT MANUFACTURING FIRMS</i>	152
MARKET SHARES	153
Bulk Drugs and APIs	154
<i>TABLE 53 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING BULK DRUGS/APIs, 2013 (%)</i>	154
<i>FIGURE 41 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING BULK DRUGS/APIs, 2013 (%)</i>	154
Solid-Dosage Forms	155
<i>TABLE 54 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING SOLID DOSAGE FORMS, 2013 (%)</i>	155
<i>FIGURE 42 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING SOLID DOSAGE FORMS, 2013 (%)</i>	155
Liquid Dosage Forms	156
Non-sterile	156
<i>TABLE 55 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING LIQUID (NON-STERILE) DOSAGE FORMS, 2013 (%)</i>	156
<i>FIGURE 43 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING LIQUID (NON-STERILE) DOSAGE FORMS, 2013 (%)</i>	157
Sterile	158
<i>TABLE 56 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING LIQUID (STERILE) DOSAGE FORMS, 2013 (%)</i>	158
<i>FIGURE 44 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING LIQUID (STERILE) DOSAGE FORMS, 2013 (%)</i>	158
Semisolid Dosage Forms	159
<i>TABLE 57 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING SEMISOLID DOSAGE FORMS, 2013 (%)</i>	159
<i>FIGURE 45 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING SEMISOLID DOSAGE FORMS, 2013 (%)</i>	160
CONTRACT RESEARCH	160
MARKET LEADERS	160
<i>TABLE 58 SERVICES PROVIDED BY CONTRACT RESEARCH FIRMS</i>	161
Market Shares	162
<i>TABLE 59 GLOBAL MARKET SHARE OF CONTRACT RESEARCH COMPANIES, 2013 (%)</i>	162
<i>FIGURE 46 GLOBAL MARKET SHARE OF CONTRACT RESEARCH COMPANIES, 2013 (%)</i>	162
CONTRACT PACKAGING	163
MARKET LEADERS	163
<i>TABLE 60 SERVICES PROVIDED BY CONTRACT PACKAGING FIRMS</i>	163
Market Share	164
<i>TABLE 61 GLOBAL MARKET SHARE OF CONTRACT PACKAGING COMPANIES, 2013 (%)</i>	164
<i>FIGURE 47 GLOBAL MARKET SHARE OF CONTRACT PACKAGING COMPANIES, 2013 (%)</i>	165
CHAPTER 10 PATENT ANALYSIS	167
PATENTS BY YEAR	167

TOPIC	PAGE NO.
<i>TABLE 62 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2013-JANUARY, 2015</i>	167
<i>FIGURE 48 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2013 TO JANUARY 2015</i>	167
PATENTS BY COMPANY	168
<i>TABLE 63 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY, 2013-JANUARY, 2015</i>	168
PATENTS BY COUNTRY	169
<i>TABLE 64 NUMBER OF U.S. PATENTS BY COUNTRY, 2013-JANUARY, 2015</i>	169
<i>FIGURE 49 NUMBER OF U.S. PATENTS BY COUNTRY, 2013 TO JANUARY 2015</i>	170
<i>TABLE 65 PATENT SHARES BY COUNTRY, 2013-JANUARY 2015 (%)</i>	170
<i>FIGURE 50 PATENT SHARES BY COUNTRY, 2013 TO JANUARY 2015 (%)</i>	171
PATENTS BY EMPHASIS	171
<i>TABLE 66 PATENTS BY EMPHASIS, 2013-JANUARY, 2015 (NO. OF PATENTS)</i>	171
<i>FIGURE 51 PATENTS BY EMPHASIS, 2013 TO JANUARY 2015 (NO. OF PATENTS)</i>	172
PATENTS BY ASSIGNEE	172
<i>TABLE 67 NUMBER OF PATENTS BY ASSIGNEE, 2013-JANUARY, 2015</i>	172
<i>FIGURE 52 NUMBER OF PATENTS BY ASSIGNEE, 2013 TO JANUARY 2015</i>	172
CHAPTER 11 CURRENT SITUATION	175
FACTORS AFFECTING THE OUTSOURCING MARKET	175
COST SAVINGS	175
DECREASING R&D SUCCESS RATES AND MOUNTING DRUG DEVELOPMENT COSTS	175
INCREASING DEMAND FOR BIOSIMILARS	176
INCREASING BURDEN FROM DISEASE	176
PATENT CLIFF	177
<i>TABLE 68 SIGNIFICANT PATENT EXPIRIES OF BIOLOGICS</i>	178
ACCESS TO CAPABILITIES/STATE-OF-THE-ART TECHNOLOGIES	178
PHARMACEUTICAL OUTSOURCING TRENDS	178
CHAPTER 12 COMPANY PROFILES	182
3M COMPANY	182
AAIPHARMA SERVICES CORP.	182
ABBVIE CONTRACT MANUFACTURING	183
AENOVA HOLDING GMBH	183
AEROGEN LTD.	184
AJINOMOTO ALTHEA TECHNOLOGIES INC.	185
ALBANY MOLECULAR RESEARCH INC. (AMRI)	185
ALKERMES PLC	186
AMCOR LTD.	187
AMERISOURCEBERGEN CORP.	188
AMPAC FINE CHEMICALS LLC	188
APTIV SOLUTIONS	189
APTUIT INC.	189
ARADIGM CORP.	190
BAXTER INTERNATIONAL	190
BCM/BOOTS MANUFACTURING	191
BOEHRINGER INGELHEIM	192
CAMBREX CORP.	192
CANGENE CORPORATION (NOW EMERGENT BIOSOLUTIONS)	193

TOPIC	PAGE NO.
CATALENT PHARMA SOLUTIONS	193
CEDARBURG HAUSER PHARMACEUTICALS INC.	194
CENEXI	194
CHARLES RIVER LABORATORIES	195
CHEMBRIDGE CORP.	195
CONFAB LABORATORIES	196
CONTRACT PHARMACEUTICALS LTD.	196
CORDEN PHARMA SWITZERLAND LLC	197
COVANCE INC.	197
DECODE GENETICS	198
DISHMAN PHARMACEUTICALS AND CHEMICALS LTD.	198
DPT LABORATORIES INC.	199
DR. REDDY'S LABORATORIES	199
DSM PHARMACEUTICAL PRODUCTS INC.	200
EVOTEC AG	200
FUJIFILM DIOSYNTH BIOTECHNOLOGY	201
GIRINDUS AG	201
GLAXOSMITHKLINE	202
GRIFOLS INTERNATIONAL S.A.	202
HERON THERAPEUTICS, INC.	203
HOSPIRA	203
HOVIONE S.A	204
ICON PLC	204
INC RESEARCH, INC.	205
JUBILANT LIFE SCIENCES LTD.	205
KP PHARMACEUTICAL TECHNOLOGY INC.	206
LIGAND PHARMACEUTICALS, INC.	206
LONZA GROUP LTD	207
LYNE LABORATORIES INC.	208
MALLINCKRODT PHARMACEUTICALS	208
MEADWESTVACO CORP.	209
MIKART INC	209
NEXTPHARMA TECHNOLOGIES	210
NORWICH PHARMA SERVICES	210
NOVAVAX, INC.	211
PACKAGING COORDINATORS INC.	212
PAREXEL INTERNATIONAL CORP.	212
PATHEON INC.	213
PERRIGO COMPANY PLC	213
PFIZER CENTRESOURCE	214
PIRAMAL ENTERPRISES LTD.	214
PPD (PHARMACEUTIAL PRODUCT DEVELOPMENT LLC)	215
PRA HEALTH SCIENCES	215
QUINTILES	216
RANBAXY LABORATORIES LTD.	216
RECIPHARM AB	217
REGIS TECHNOLOGIES INC.	217

TOPIC	PAGE NO.
SCHOTT PHARMACEUTICAL PACKAGING	218
SKYEPHARMA PLC	218
TAKEDA PHARMACEUTICALS	219
THEOREM CLINICAL RESEARCH INC.	219
VALEANT PHARMACEUTICALS INTERNATIONAL INC.	220
VETTER PHARMA INTERNATIONAL GMBH	220
WOCKHARDT LTD.	221
WUXI APP TEC	221
ZACH SYSTEM S.P.A	222
CHAPTER 13 APPENDIX	224
ABBREVIATIONS	224

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR CONTRACT PHARMACEUTICAL MANUFACTURING, RESEARCH AND PACKAGING BY SEGMENT, THROUGH 2019 (\$ BILLIONS)	7
TABLE 1 KEY DEVELOPMENTS IN THE HISTORY OF OUTSOURCING	11
TABLE 2 ADVANTAGES AND DISADVANTAGES OF CONTRACT MANUFACTURING	21
TABLE 3 PHARMACEUTICAL MANUFACTURERS THAT RECEIVED WARNING LETTERS, 2014	36
TABLE 4 PHARMACEUTICAL MANUFACTURERS THAT RECEIVED WARNING LETTERS, 2013	37
TABLE 5 PHARMACEUTICAL MANUFACTURERS THAT RECEIVED WARNING LETTERS, 2012	38
TABLE 6 PHARMACEUTICAL MANUFACTURERS THAT RECEIVED WARNING LETTERS, 2011	39
TABLE 7 REGULATORY APPROVALS OF CONTRACT MANUFACTURERS AND FACILITIES, 2014	40
TABLE 8 REGULATORY APPROVALS OF CONTRACT MANUFACTURERS AND FACILITIES, 2013	41
TABLE 9 REGULATORY APPROVALS OF CONTRACT MANUFACTURERS AND FACILITIES, 2012	41
TABLE 10 REGULATORY APPROVALS OF CONTRACT MANUFACTURERS AND FACILITIES, 2011	42
TABLE 11 GLOBAL REVENUE FOR BULK DRUG/APIS THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ MILLIONS)	61
TABLE 12 GLOBAL REVENUE FOR CONTRACT MANUFACTURING OF VARIOUS DOSAGE FORMS, THROUGH 2019 (\$ MILLIONS)	65
TABLE 13 GLOBAL REVENUE FOR SOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ MILLIONS)	68
TABLE 14 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (NON-STERILE) THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ MILLIONS)	72
TABLE 15 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (STERILE) THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ MILLIONS)	73
TABLE 16 GLOBAL REVENUE FOR SEMISOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ MILLIONS)	76
TABLE 17 GLOBAL REVENUE FOR SOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, THROUGH 2019 (\$ MILLIONS)	78
TABLE 18 GLOBAL MARKET SHARE OF SOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)	78
TABLE 19 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (NON-STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, THROUGH 2019 (\$ MILLIONS)	80
TABLE 20 GLOBAL MARKET SHARE OF LIQUID DOSAGE FORMS (NON-STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)	81
TABLE 21 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, THROUGH 2019 (\$ MILLIONS)	83
TABLE 22 GLOBAL MARKET SHARE OF LIQUID DOSAGE FORMS (STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)	84
TABLE 23 GLOBAL REVENUE FOR SEMISOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, THROUGH 2019 (\$ MILLIONS)	86
TABLE 24 GLOBAL MARKET SHARE OF SEMISOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)	87
TABLE 25 SOME CONTRACTING COMPANIES PROVIDING DRUG-DELIVERY SYSTEMS	90

TABLE HEADING	PAGE NO.
TABLE 26 GLOBAL REVENUE FOR ADVANCED DRUG DELIVERY SYSTEMS THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ MILLIONS)	91
TABLE 27 GLOBAL REVENUE FOR ADVANCED DRUG DELIVERY SYSTEMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, THROUGH 2019 (\$ MILLIONS)	93
TABLE 28 GLOBAL MARKET SHARE OF ADVANCED DRUG DELIVERY SYSTEMS THROUGH CONTRACT MANUFACTURING BY TYPE, 2013 (%)	94
TABLE 29 GLOBAL REVENUE FOR OTC AND NUTRACEUTICALS THROUGH CONTRACT MANUFACTURING BY REGION, THROUGH 2019 (\$ BILLIONS)	97
TABLE 30 GLOBAL REVENUE FOR OTC AND NUTRACEUTICALS THROUGH CONTRACT MANUFACTURING BY FORMULATION, THROUGH 2019 (\$ BILLIONS)	99
TABLE 31 GLOBAL MARKET SHARE OF OTC AND NUTRACEUTICALS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)	99
TABLE 32 GLOBAL REVENUE FOR CONTRACT MANUFACTURING DRUGS BY THERAPEUTIC CATEGORY, THROUGH 2019 (\$ MILLIONS)	106
TABLE 33 GLOBAL MARKET SHARE OF VARIOUS THERAPEUTIC CATEGORIES IN CONTRACT MANUFACTURING, 2013 (%)	107
TABLE 34 GLOBAL REVENUE FOR CONTRACT RESEARCH BY DISCIPLINE, THROUGH 2019 (\$ MILLIONS)	113
TABLE 35 GLOBAL MARKET SHARE OF CONTRACT RESEARCH BY DISCIPLINE, 2013 (%)	113
TABLE 36 GLOBAL REVENUE FOR CONTRACT RESEARCH BY REGION, THROUGH 2019 (\$ MILLIONS)	117
TABLE 37 GLOBAL MARKET SHARE OF CONTRACT RESEARCH BY REGION, 2013 (%)	117
TABLE 38 GLOBAL REVENUE FOR CONTRACT CLINICAL RESEARCH BY REGION, THROUGH 2019 (\$ MILLIONS)	119
TABLE 39 GLOBAL REVENUE FOR CONTRACT DRUG DISCOVERY BY REGION, THROUGH 2019 (\$ MILLIONS)	121
TABLE 40 GLOBAL REVENUE FOR CONTRACT ANALYTICAL RESEARCH MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	123
TABLE 41 GLOBAL REVENUE FOR OTHER CONTRACT RESEARCH MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	125
TABLE 42 GLOBAL REVENUE FOR CONTRACT RESEARCH BY THERAPEUTIC AREA, THROUGH 2019 (\$ MILLIONS)	132
TABLE 43 GLOBAL MARKET SHARE OF CONTRACT RESEARCH BY THERAPEUTIC AREA, 2013 (%)	133
TABLE 44 GLOBAL REVENUE OF CONTRACT PACKAGING BY TYPE, THROUGH 2019 (\$ MILLIONS)	137
TABLE 45 GLOBAL REVENUE OF PRIMARY PACKAGING BY TYPE, THROUGH 2019 (\$ MILLIONS)	139
TABLE 46 GLOBAL MARKET SHARE OF CONTRACT PACKAGING BY TYPE, 2013 (%)	140
TABLE 47 GLOBAL REVENUE OF CONTRACT PACKAGING BY REGION, THROUGH 2019 (\$ MILLIONS)	143
TABLE 48 GLOBAL MARKET SHARE OF CONTRACT PACKAGING BY REGION, 2013 (%)	144
TABLE 49 GLOBAL REVENUE FOR PRIMARY PACKAGING BY REGION, THROUGH 2019 (\$ MILLIONS)	146
TABLE 50 GLOBAL REVENUE FOR SECONDARY PACKAGING BY REGION, THROUGH 2019 (\$ MILLIONS)	148
TABLE 51 GLOBAL REVENUE FOR OTHER PACKAGING BY REGION, THROUGH 2019 (\$ MILLIONS)	150
TABLE 52 SERVICES PROVIDED BY CONTRACT MANUFACTURING FIRMS	152
TABLE 53 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING BULK DRUGS/APIS, 2013 (%)	154

TABLE HEADING	PAGE NO.
TABLE 54 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING SOLID DOSAGE FORMS, 2013 (%)	155
TABLE 55 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING LIQUID (NON-STERILE) DOSAGE FORMS, 2013 (%)	156
TABLE 56 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING LIQUID (STERILE) DOSAGE FORMS, 2013 (%)	158
TABLE 57 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING SEMISOLID DOSAGE FORMS, 2013 (%)	159
TABLE 58 SERVICES PROVIDED BY CONTRACT RESEARCH FIRMS	161
TABLE 59 GLOBAL MARKET SHARE OF CONTRACT RESEARCH COMPANIES, 2013 (%)	162
TABLE 60 SERVICES PROVIDED BY CONTRACT PACKAGING FIRMS	163
TABLE 61 GLOBAL MARKET SHARE OF CONTRACT PACKAGING COMPANIES, 2013 (%)	164
TABLE 62 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2013-JANUARY, 2015	167
TABLE 63 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY, 2013-JANUARY, 2015	168
TABLE 64 NUMBER OF U.S. PATENTS BY COUNTRY, 2013-JANUARY, 2015	169
TABLE 65 PATENT SHARES BY COUNTRY, 2013-JANUARY 2015 (%)	170
TABLE 66 PATENTS BY EMPHASIS, 2013-JANUARY, 2015 (NO. OF PATENTS)	171
TABLE 67 NUMBER OF PATENTS BY ASSIGNEE, 2013-JANUARY, 2015	172
TABLE 68 SIGNIFICANT PATENT EXPIRIES OF BIOLOGICS	178

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR CONTRACT PHARMACEUTICAL MANUFACTURING, RESEARCH AND PACKAGING BY SEGMENT, 2012-2019 (\$ BILLIONS)	7
FIGURE 1 GLOBAL REVENUE FOR BULK DRUG/APIS THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ MILLIONS)	62
FIGURE 2 GLOBAL REVENUE FOR CONTRACT MANUFACTURING OF VARIOUS DOSAGE FORMS, 2012-2019 (\$ MILLIONS)	65
FIGURE 3 GLOBAL REVENUE FOR SOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ MILLIONS)	68
FIGURE 4 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (NON-STERILE) THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ MILLIONS)	72
FIGURE 5 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (STERILE) THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ MILLIONS)	73
FIGURE 6 GLOBAL REVENUE FOR SEMISOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ MILLIONS)	76
FIGURE 7 GLOBAL REVENUE FOR SOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2012-2019 (\$ MILLIONS)	78
FIGURE 8 GLOBAL MARKET SHARE OF SOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)	79
FIGURE 9 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (NON-STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2012-2019 (\$ MILLIONS)	81
FIGURE 10 GLOBAL MARKET SHARE OF LIQUID DOSAGE FORMS (NON-STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)	82
FIGURE 11 GLOBAL REVENUE FOR LIQUID DOSAGE FORMS (STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2012-2019 (\$ MILLIONS)	83
FIGURE 12 GLOBAL MARKET SHARE OF LIQUID DOSAGE FORMS (STERILE) THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)	84
FIGURE 13 GLOBAL REVENUE FOR SEMISOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2012-2019 (\$ MILLIONS)	86
FIGURE 14 GLOBAL MARKET SHARE OF SEMISOLID DOSAGE FORMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2013 (%)	87
FIGURE 15 GLOBAL REVENUE FOR ADVANCED DRUG DELIVERY SYSTEMS THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ MILLIONS)	91
FIGURE 16 GLOBAL REVENUE FOR ADVANCED DRUG DELIVERY SYSTEMS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2012-2019 (\$ MILLIONS)	93
FIGURE 17 GLOBAL MARKET SHARE OF ADVANCED DRUG DELIVERY SYSTEMS THROUGH CONTRACT MANUFACTURING BY TYPE, 2013 (%)	95
FIGURE 18 GLOBAL REVENUE FOR OTC AND NUTRACEUTICALS THROUGH CONTRACT MANUFACTURING BY REGION, 2012-2019 (\$ BILLIONS)	98
FIGURE 19 GLOBAL REVENUE FOR OTC AND NUTRACEUTICALS THROUGH CONTRACT MANUFACTURING BY FORMULATION, 2012-2019 (\$ BILLIONS)	99
FIGURE 20 GLOBAL MARKET SHARE OF OTC AND NUTRACEUTICALS THROUGH CONTRACT MANUFACTURING BY DOSAGE TYPE, 2013 (%)	100
FIGURE 21 GLOBAL REVENUE FOR CONTRACT MANUFACTURING DRUGS BY THERAPEUTIC CATEGORY, 2012-2019 (\$ MILLIONS)	106
FIGURE 22 GLOBAL MARKET SHARE OF VARIOUS THERAPEUTIC CATEGORIES IN CONTRACT MANUFACTURING, 2013 (%)	107
FIGURE 23 GLOBAL REVENUE FOR CONTRACT RESEARCH BY DISCIPLINE, 2012-2019 (\$ MILLIONS)	113
FIGURE 24 GLOBAL MARKET SHARE OF CONTRACT RESEARCH BY DISCIPLINE, 2013 (%)	114

FIGURE TITLE	PAGE NO.
FIGURE 25 GLOBAL REVENUE FOR CONTRACT RESEARCH MARKET BY REGION, 2012-2019 (\$ MILLIONS)	117
FIGURE 26 GLOBAL MARKET SHARE OF CONTRACT RESEARCH MARKET BY REGION, 2013 (%)	118
FIGURE 27 GLOBAL REVENUE FOR CONTRACT CLINICAL RESEARCH BY REGION, 2012-2019 (\$ MILLIONS)	120
FIGURE 28 GLOBAL REVENUE FOR CONTRACT DRUG DISCOVERY BY REGION, 2012-2019 (\$ MILLIONS)	121
FIGURE 29 GLOBAL REVENUE FOR CONTRACT ANALYTICAL RESEARCH MARKET BY REGION, 2012-2019 (\$ MILLIONS)	124
FIGURE 30 GLOBAL REVENUE FOR OTHER CONTRACT RESEARCH MARKET BY REGION, 2012-2019 (\$ MILLIONS)	125
FIGURE 31 GLOBAL REVENUE FOR CONTRACT RESEARCH BY THERAPEUTIC AREA, 2012-2019 (\$ MILLIONS)	132
FIGURE 32 GLOBAL MARKET SHARE OF CONTRACT RESEARCH BY THERAPEUTIC AREA, 2013 (%)	133
FIGURE 33 GLOBAL REVENUE OF CONTRACT PACKAGING BY TYPE, 2012-2019 (\$ MILLIONS)	138
FIGURE 34 GLOBAL REVENUE OF PRIMARY PACKAGING BY TYPE, 2012-2019 (\$ MILLIONS)	139
FIGURE 35 GLOBAL MARKET SHARE OF CONTRACT PACKAGING BY TYPE, 2013 (%)	140
FIGURE 36 GLOBAL REVENUE OF CONTRACT PACKAGING BY REGION, 2012-2019 (\$ MILLIONS)	143
FIGURE 37 GLOBAL MARKET SHARE OF CONTRACT PACKAGING BY REGION, 2013 (%)	144
FIGURE 38 GLOBAL REVENUE FOR PRIMARY PACKAGING BY REGION, 2012-2019 (\$ MILLIONS)	146
FIGURE 39 GLOBAL REVENUE FOR SECONDARY PACKAGING BY REGION, 2012-2019 (\$ MILLIONS)	148
FIGURE 40 GLOBAL REVENUE FOR OTHER PACKAGING BY REGION, 2012-2019 (\$ MILLIONS)	150
FIGURE 41 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING BULK DRUGS/APIs, 2013 (%)	154
FIGURE 42 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING SOLID DOSAGE FORMS, 2013 (%)	155
FIGURE 43 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING LIQUID (NON-STERILE) DOSAGE FORMS, 2013 (%)	157
FIGURE 44 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING LIQUID (STERILE) DOSAGE FORMS, 2013 (%)	158
FIGURE 45 GLOBAL MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING SEMISOLID DOSAGE FORMS, 2013 (%)	160
FIGURE 46 GLOBAL MARKET SHARE OF CONTRACT RESEARCH COMPANIES, 2013 (%)	162
FIGURE 47 GLOBAL MARKET SHARE OF CONTRACT PACKAGING COMPANIES, 2013 (%)	165
FIGURE 48 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2013 TO JANUARY 2015	167
FIGURE 49 NUMBER OF U.S. PATENTS BY COUNTRY, 2013 TO JANUARY 2015	170
FIGURE 50 PATENT SHARES BY COUNTRY, 2013 TO JANUARY 2015 (%)	171
FIGURE 51 PATENTS BY EMPHASIS, 2013 TO JANUARY 2015 (NO. OF PATENTS)	172
FIGURE 52 NUMBER OF PATENTS BY ASSIGNEE, 2013 TO JANUARY 2015	172